The 12-month price targets, analyzed by analysts, offer insights with an average target of $352.0, a high estimate of $425.00 ...

Fintel reports that on April 25, 2025, Wells Fargo downgraded their outlook for United Therapeutics (NasdaqGS:UTHR) from ...

Wall Street expects a year-over-year increase in earnings on higher revenues when United Therapeutics (UTHR) reports results for the quarter ended March 2025. While this widely-known consensus outlook ...

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C., April 21, 2025--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that recent research across its ...

BofA upgraded United Therapeutics (UTHR) to Neutral from Underperform with a $314 price target Stay Ahead of the Market: Discover ...

As previously reported, BofA analyst Jason Gerberry upgraded United Therapeutics (UTHR) to Neutral from Underperform with an unchanged price ...

It is worth considering United Therapeutics (UTHR), which belongs to the Zacks Medical - Drugs industry. This drugmaker has an established record of topping earnings estimates, especially when ...

Fintel reports that on April 21, 2025, B of A Securities upgraded their outlook for United Therapeutics (NasdaqGS:UTHR) from Underperform to Neutral. As of April 2, 2025, the average one-year ...

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C., April 16, 2025--United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its first quarter 2025 financial results ...

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life ...